[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 4 of about 4
1. Kumar S, Masood N, Shaikh AJ, Valimuhammad AT, Haider G, Lal A, Niamatullah N: Clinical presentation and outcomes of patients with biliary malignancies: the Aga Khan University experience. Asian Pac J Cancer Prev; 2009 Jul-Sep;10(3):463-6
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pathological diagnosis was confirmed in 155 (63.2%) patients, adenocarcinoma (94.8%) being the predominant type.
  • Metastasis was seen in 204 (83.3%) patients, with liver and abdominal lymph nodes being the frequent sites of metastasis.
  • Common bile duct stricture was seen in 78 patients and stenting was successful in 73 patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bile Duct Neoplasms / drug therapy. Bile Ducts, Intrahepatic / drug effects. Cholangiocarcinoma / drug therapy. Gallbladder Neoplasms / drug therapy. Liver Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19640192.001).
  • [ISSN] 2476-762X
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


2. Berr F, Wiedmann M, Tannapfel A, Halm U, Kohlhaw KR, Schmidt F, Wittekind C, Hauss J, Mössner J: Photodynamic therapy for advanced bile duct cancer: evidence for improved palliation and extended survival. Hepatology; 2000 Feb;31(2):291-8
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy for advanced bile duct cancer: evidence for improved palliation and extended survival.
  • Median survival time of nonresectable hilar bile duct cancer is only 4 to 6 months owing to tumor spread in the biliary tree, refractory cholestasis, and sepsis or liver failure.
  • We explored whether local photodynamic therapy of nonresectable bile duct cancer could improve survival.
  • Twenty-three consecutive patients (8 women, 15 men; 67 +/- 14 years) with nonresectable bile duct cancer (Bismuth type III n = 2, type IV n = 21) were treated with photodynamic therapy and biliary endoprosthesis.
  • Photofrin (QLT Pharmaceuticals, Vancouver, Canada) (2 mg/kg body weight intravenously) was photoactivated after 1 to 4 days with laser light (630 nm; 242 J/cm(2)) via endoscopic retrograde access.
  • All patients, except 1 with diffuse liver metastases, improved in cholestasis, performance, and quality of life.
  • Photodynamic therapy can prevent tumor occlusion of hilar bile ducts.
  • [MeSH-major] Adenocarcinoma / drug therapy. Bile Duct Neoplasms / drug therapy. Palliative Care. Photochemotherapy

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10655248.001).
  • [ISSN] 0270-9139
  • [Journal-full-title] Hepatology (Baltimore, Md.)
  • [ISO-abbreviation] Hepatology
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


3. Wernicke J, Pangallo B, Wang F, Murray I, Henck JW, Knadler MP, D'Souza DN, Uetrecht JP: Hepatic effects of duloxetine-I: non-clinical and clinical trial data. Curr Drug Saf; 2008 May;3(2):132-42
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Seven of 23,000 duloxetine- and 2/6000 placebo-treated patients met criteria for modified Hy's rule (significant elevation of both ALT and total bilirubin) but were complicated by contributing factors such as excessive alcohol consumption (n=3), gall stones, common bile duct calculus, hepatitis C, and liver adenocarcinoma (n=1 each).
  • CONCLUSIONS: Duloxetine has an effect on the liver, manifested by transient, self-limiting transaminase elevations.
  • Rare events characterized as hepatocellular injury, cholestatic injury, or mixed type of hepatic injury have been reported.
  • The pattern of liver effects was different from that in laboratory animals.
  • [MeSH-major] Adrenergic Uptake Inhibitors / adverse effects. Drug-Induced Liver Injury. Liver / drug effects. Serotonin Uptake Inhibitors / adverse effects. Thiophenes / adverse effects
  • [MeSH-minor] Alanine Transaminase / blood. Alkaline Phosphatase / blood. Animals. Aspartate Aminotransferases / blood. Bilirubin / blood. Biomarkers / blood. Clinical Trials as Topic. Consumer Product Safety. Drug Evaluation, Preclinical. Duloxetine Hydrochloride. Humans. Liver Diseases / enzymology. Risk Assessment. Risk Factors. Species Specificity

  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • Hazardous Substances Data Bank. DULOXETINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Curr Drug Saf. 2009 Jan;4(1):94
  • (PMID = 18690991.001).
  • [ISSN] 2212-3911
  • [Journal-full-title] Current drug safety
  • [ISO-abbreviation] Curr Drug Saf
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United Arab Emirates
  • [Chemical-registry-number] 0 / Adrenergic Uptake Inhibitors; 0 / Biomarkers; 0 / Serotonin Uptake Inhibitors; 0 / Thiophenes; 9044SC542W / Duloxetine Hydrochloride; EC 2.6.1.1 / Aspartate Aminotransferases; EC 2.6.1.2 / Alanine Transaminase; EC 3.1.3.1 / Alkaline Phosphatase; RFM9X3LJ49 / Bilirubin
  • [Number-of-references] 30
  •  go-up   go-down






Advertisement